MAP LC3α Inhibitors
MAP LC3α inhibitors operate through distinct mechanisms, each targeting specific aspects of the autophagy pathway to regulate MAP LC3α's activity. Primarily, these inhibitors disrupt the initiation of autophagy by targeting kinases and enzymes essential for the early stages. This disruption leads to reduced lipidation and recruitment of MAP LC3α to autophagosomes, hindering its crucial role in autophagosome formation. Additionally, some of these inhibitors focus on the production of key lipid signaling molecules, further impacting MAP LC3α's involvement in autophagosome nucleation and emphasizing the importance of initial signaling events in autophagy regulation.
Another crucial aspect of inhibition involves impairing autophagosome maturation and turnover. By blocking the fusion of autophagosomes with lysosomes, these inhibitors cause an accumulation of autophagosomes, indirectly reducing MAP LC3α's functional role as it becomes trapped in these structures. Moreover, targeting enzymes responsible for MAP LC3α processing and delipidation diminishes its availability and functionality, essential for its autophagic action. Collectively, these inhibitors showcase a multifaceted approach to modulating autophagy, demonstrating the complexity of signaling pathways and molecular processes involved in this critical cellular mechanism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MHY1485 | 326914-06-1 | sc-507522 | 10 mg | $140.00 | ||
MHY1485 is an mTOR activator. By activating mTOR, it negatively regulates autophagy, counteracting the process in which MAP LC3α is involved. Enhanced mTOR activity leads to the inhibition of ULK1 complex formation, essential for autophagy initiation, thereby reducing MAP LC3α lipidation and its autophagic activity. | ||||||
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $347.00 $2710.00 | 5 | |
Verteporfin, without light activation, acts as an autophagy inhibitor by interacting with YAP1, a regulator of the Hippo pathway. This interaction disrupts the formation of the YAP1-TEAD complex, indirectly influencing autophagy and subsequently leading to the reduction of MAP LC3α's recruitment to autophagosomes. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Concanamycin A, a V-ATPase inhibitor like bafilomycin A1, prevents autophagosome-lysosome fusion. This inhibition leads to autophagosome accumulation and indirectly reduces the functional activity of MAP LC3α by hindering its role in autophagosome maturation and turnover. | ||||||
NSC 185058 | 39122-38-8 | sc-507531 | 1 mg | $85.00 | ||
NSC 185058 disrupts ATG4B's activity, an enzyme crucial for MAP LC3α processing. By inhibiting ATG4B, this compound prevents the delipidation of MAP LC3α, essential for its recycling and sustained autophagic flux, thus indirectly inhibiting MAP LC3α activity. | ||||||
SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
SAR405, a specific inhibitor of Vps34, impedes the production of PI3P, a key initiator of autophagy. This inhibition decreases autophagosome formation, subsequently reducing the recruitment and lipidation of MAP LC3α, crucial for its autophagic function. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 targets deubiquitinating enzymes USP10 and USP13, leading to the degradation of the Beclin1-Vps34 complex, integral to autophagosome formation. This degradation reduces MAP LC3α's recruitment and function in autophagosome biogenesis. | ||||||
PIK-III | 1383716-40-2 | sc-507530 | 5 mg | $170.00 | ||
PIK-III, a selective inhibitor of Vps34, specifically targets the production of PI3P, a lipid essential for the initiation of autophagy. By inhibiting Vps34, PIK-III reduces autophagosome nucleation and hence the activity of MAP LC3α in autophagy. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Rocaglamide, a natural product, has been shown to inhibit autophagy. It does so by influencing signaling pathways upstream of autophagy initiation, which indirectly leads to the reduction of MAP LC3α lipidation and its incorporation in autophagosomes. | ||||||